Mankind Pharma unveils drug to treat diabetes, heart failure and CKD
22 June 2021 | News
Justoza is Dapagliflozin brand and has been approved by US FDA
Image Credit: shutterstock
Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat diabetes, heart failure and chronic kidney disease (CKD).
The active pharmaceutical ingredient is procured from the DMF (Drug Master File) facility approved by US FDA, EU GMP and WHO GMP, which ensures the highest global efficacy and safety standards. It is believed that the quality of DMF grade facility product is of the highest standard in terms of safety and efficacy.
Speaking on the launch, Atish Majumdar, President, Mankind Pharma, said, “Launching API DMF Grade Dapagliflozin is an innovative futuristic approach to provide the best in class quality to the patients. This is just the beginning, we are committed to adding more medicines to the list. Serving life is a mission in progress for us at Mankind Pharma.”
